Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase II single-arm, single-site, open label clinical trial with r/r HL patients,
aimed to determine whether a RadVax approach using low-dose RT added to nivolumab can improve
response among patients who do not achieve a CR to nivolumab alone. The long-term goal is to
develop an effective regimen for r/r HL patients.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania